Blood Research

2008 Lymphoma Drug Pipeline Update

Lymphoma Drug Pipeline Update 2008, Bioseeker, April 2008

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 180 therapeutics targeting lymphoma, from early preclinical to marketed drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 103 different targets. These targets are further categorized on the CD-ROM by 39 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Lymphoma Drug Pipeline Update is organized.

Drug Pipeline Update at a Glance
Investigators Includes more than 140 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators. There are more than 300 names. Developmental stage: This Drug Pipeline Update contains more than 180 drugs in active development for the treatment of lymphoma (including: B-cell, T-cell, Hodgkin`s, and non-Hodgkin`s):
27 marketed drugs
> 20 projects in Phase III
> 90 projects in Phase II
> 55 projects in Phase I
> 35 projects in Preclinical

Targets Identified drugs are linked to more than 103 different targets, divided into 39 classifications of molecular function:
- Carboxy-lyase activity
- Catalytic activity
- Cell adhesion molecule activity
- Cysteine-type peptidase activity
- Cytokine activity
- DNA binding
- DNA repair protein
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- G-protein coupled receptor activity
- Glutathione transferase activity
- Hormone activity
- Hydrolase activity
- Kinase activity
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Lipid phosphatase activity
- MHC class I receptor activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Phosphorylase activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein tyrosine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- RNA binding
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Superoxide dismutase activity
- T cell receptor activity
- Transcription factor activity
- Transcription regulator activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity

Identified targets are categorized into 19 different primary and alternate sub-cellular localizations:
- Centrosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Golgi apparatus
- Integral to membrane
- Lysosome
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nucleolus
- Nucleus
- Perinuclear region
- Peroxisome
- Plasma membrane

Target Expression Profile Direct links are provided from inside the application to 65 protein expression profiles of 58 drug targets in various human tissues and cancer types, cell lines and primary cells, includin u to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their invovlement in different cellular pathways, according to BioCarta, KEGG and NetPath.
- BioCarta 186 Pathways
- KEGG 62 Pathways
- NetPath 20 Signaling Pathways

Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells

Targeted Pathways
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.

Bioseeker, April 2008
http://www.researchandmarkets.com/reports/328860

© 2008 hematopathologist.com. (RSS)